

Dennis L. Panicali et al.

Application No.:

10/660,369

09/11/2003

Confirmation No.:

Examiner: Customer No.: 1614

5464

To be assigned 50187

For:

Filed:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE

IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR

Group No.:

EFFECTS IN VIVO

## CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Linda M. Ginsberg

(type or)print name ng paper)

MAIL STOP PETITION Director of the US Patent and Trademark Office PO Box 1450

Alexandria, VA 22313-1450

Date

# AMENDMENT, REQUEST AND FEE TO DELETE AND/OR ADD TO ORIGINAL ERRONEOUSLY NAMED OR NOT NAMED INVENTOR(S) IN—NONPROVISIONAL APPLICATION—DECLARATION (37 C.F.R. § 1.48(a))

- This amendment and request is to correct the incorrect original naming of inventor(s) in 1. the declaration under 37 C.F.R. § 1.48(a) as set forth and filed on January 22, 2004.
- 2. Addition of Inventor:

Jeffrey Schlom

- 3. Attachments:
  - Statement of Non-Deceptive Intent, Jeffrey Schlom, as required by 37 C.F.R. (a) § 1.48(a);

12/13/2005 EFLORES 00000020 500850 10660369

130.00 DA 01 FC:1464

In re application of:

Dennis L. Panicali et al.

Application No.:

10/660,369

Group No.:

1614

Filed: Confirmation No.: 09/11/2003 5464 Examiner: Customer No.: To be assigned 50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY

PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN VIVO

- (b) Assent of the Assignee to Correct Inventorship and Statement Under 37 C.F.R. § 3.73(b):
  - (i) Therion Biologics Corporation; and
  - (ii) The Trustees of the Leland Stanford Junior University
- 4. Fee Payment (37 C.F.R. § 1.17(i))

The fee required by 37 C.F.R. § 1.17(h) is paid as follows:

The Commissioner is authorized to charge the NIXON PEABODY LLP Deposit Account No. 50-0850 in the amount of \$130.00. Any fee deficiencies or overpayments may be charged/credited to said account. A duplicate copy of this paper is submitted herewith.

Date: December 7, 2005

Respectfully submitted,

Ronald I. Eisenstein (Reg. No. 30,628)

NIXON PEABODY LLP

100 Summer Street Boston, MA 02110 DEC 1 2 2005

application of: Dennis L. Panicali et al.

Application No.:

10/660,369

Group No.:

1614

Filed:

09/11/2003

Examiner:

To be assigned

Confirmation No.:

5464

Customer No.:

50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1

AND LFA-3 AND INDUCE IMMUNOSTIMULATORY

PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN

**VIVO** 

#### CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Linda M. Ginsberg


(type of print name of person mailing paper)

son maili**h**é per)

MAIL STOP PETITION Director of the US Patent and Trademark Office PO Box 1450 Alexandria, VA 22313-1450

# STATEMENT OF NON-DECEPTIVE INTENT TO ACCOMPANY REQUEST FOR CORRECTION OF INVENTORSHIP **UNDER 37 C.F.R. §1.48(A)**

I, the person who is being added as an inventor by the Request for Correction of Inventorship being submitted concurrently herewith to correct the inventorship of this patent application do hereby declare that the inventorship error in failing to include my name as an inventor on this patent occurred without any deceptive intention on my part.



which is described and claimed in:

Attorney's Docket No. 700953-54440

Page 1 of 4

#### SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO

		the specification attached hereto.
2003;	×	the specification in U.S. Application Serial Number 10/660,369 filed on September 11
		the specification in PCT International Application Number filed on as amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:							
Application No.	Filing Date	Country	Priority Claimed under 35 U.S.C. §119?				
-			□YES □NO				
			□YES □NO				
			□YES □NO				
			□YES □NO				

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to

disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. App	olications	or PCT	International Appl under 35 U.S	_	nating the U.	S-Benefit
	U.S. A	plication	·		atus (Check C	One)
Application Seria	Application Serial No. U.S. Filing Date				Pending	Abandoned
					ļ	
PCT Applica	tions De	signatir	ng the U.S.			
Application No.	Filing	Date	U.S. Serial No. Assigned			
		•				

# CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (35 U.S.C. §119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

<u>Applicant</u>	Provisional Application Number	Filing Date
Dennis L. Panicali, et al.	60/410,161	September 12, 2002

**POWER OF ATTORNEY**: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I. Eisenstein	(Reg. No. 30,628)	David S. Resnick	(Reg. No. 34,235)	Michael L. Goldman	(Reg. No. 30,727)
Nicole L.M. Valtz	(Reg. No. 47,150)	Leena Karttunen	(37 CFR Sec. 10.9(b)) Georgia	Evans (Reg. No.	44,957)
Lisa A. Dolak	(Reg. No. 35,491)	Joseph Noto	(Reg. No. 32,163))	Gunnar G. Leinberg	(Reg. No. 35,584)
Edwin V Markel	(Reg No 40 087)		, ,		

# **SEND CORRESPONDENCE TO:** David S. Resnick

NIXON PEABODY LLP
100 Summer Street

Boston, Massachusetts 02110

# DIRECT TELEPHONE CALLS TO:

David S. Resnick (617) 345-6057


	FULL NAME OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	PANICALI	DENNIS	L.
2	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
0	CITIZENSHIP	Acton	MA	U.S.
	POST OFFICE	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
	ADDRESS	114 Nonset Path	Acton	MA 01720

	FULL NAME OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	LEVY	RONALD	
2	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
2	CITIZENSHIP	Stanford	CA	U.S.
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
		966 Mears Court	Stanford	CA 94305

	FULL NAME OF INVENTOR	SCHLOM	JEFFREY	MIDDLE NAME
2 0 3	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP U.S.
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
		10301 Sorrel Ave.	Potomac	MD 20854

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 - Dennis L. Panicali	Date:
James 1	8-22-05
Signature of Inventor 202 - Ronald Levy	Date:
Signature of Inventor 203 – Jeffrey Schlom	Date:



which is described and claimed in:

Attorney's Docket No. 700953-54440

Page 1 of 4

#### SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO

	the specification attached hereto.
区 September 11,	the specification in U.S. Application Serial Number 10/660,369 filed on 2003;
	the specification in PCT International Application Number filed on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:						
Application No.	Filing Date	Country	Priority Claimed under 35 U.S.C. §119?			
			□YES □NO			
			□YES □NO			
			□YES □NO			
			□YES □NO			

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

Prior U.S. Ap	plications	or PC	Γ International Appl under 35 U.S	_	ating the U.S	-Benefit
	<u>U.S. A</u>	pplicati	<u>ons</u>	Sta	atus (Check C	)ne)
Application Serial No. U.S. Filing Dat			U.S. Filing Date	Patented	Pending	Abandoned
PCT Applica	tions Des	ignatin	g the U.S.			
Application No.	Filing	Date	U.S. Serial No. Assigned			

# CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (35 U.S.C. §119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date
Dennis L. Panicali, et al.	60/410,161	September 12, 2002

**POWER OF ATTORNEY**: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I. Eisenstein (Reg. No. 30,628) David S. Resnick (Reg. No. 34,235) Michael L. Goldman (Reg. No. 30,727) Nicole L.M. Valtz (Reg. No. 47,150) Leena Karttunen (37 CFR Sec. 10.9(b)) Georgia Evans (Reg. No. 44,957) Lisa A. Dolak (Reg. No. 35,491) Joseph Noto (Reg. No. 32,163)) Gunnar G. Leinberg (Reg. No. 35,584) Edwin V. Merkel (Reg. No. 40,087)

# SEND CORRESPONDENCE TO: David S. Resnick NIXON PEABODY LLP 100 Summer Street Boston, Massachusetts 02110 DIRECT TELEPHONE CALLS TO: David S. Resnick (617) 345-6057


	OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	PANICALI	DENNIS	L.
2	RESIDENCE	CITY	STATE OR FOREIGN	COUNTRY OF
0	&		COUNTRY	CITIZENSHIP
1	CITIZENSHIP	Acton	MA	U.S.
	POST	POST OFFICE	CITY	STATE OR COUNTRY
	OFFICE	ADDRESS		AND ZIP CODE
	ADDRESS	114 Nonset Path	Acton	MA 01720

	FULL NAME OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	LEVY	RONALD	
2	RESIDENCE &	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
2	CITIZENSHIP	Stanford	CA	U.S.
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
		966 Mears Court	Stanford	CA 94305

	FULL NAME OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	SCHLOM	JEFFREY	
2	&	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
3	CITIZENSHIP			U.S.
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
		10301 Sorrel Ave.	Potomac	MD 20854

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 – Dennis L. Panicali	Date:
Signature of Inventor 202 – Ronald Levy	Date:
Avall for	10/4/05
Signature of Inventor 203 – Jeffrey Schlom	Date:



Attorney's Docket No. 700953-54440

Page 1 of 4

#### SUPPLEMENTAL DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I hereby declare that: My residence, post office address and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed at 201) below or an original, first and joint inventor (if plural names are listed at 201-208 below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1, AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN-VIVO

which is	s describ	ped and claimed in:
		the specification attached hereto.
2003;	×	the specification in U.S. Application Serial Number 10/660,369 filed on September 11,
		the specification in PCT International Application Number filed on , as amended on

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, §1.56(a). I hereby claim foreign priority benefits under Title 35, United States Code, §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

Prior Foreign/P	Prior Foreign/PCT Applications and Any Priority Claims Under 35 U.S.C. §119:					
Application No.	Filing Date	Country	Priority Claimed under 35 U.S.C. §119?			
			□YES □NO			
			□YES □NO			
			□YES □NO			
			□YES □NO			

I hereby claim the benefit under 35 U.S.C. §120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below, and, insofar as the subject matter of each of the claims of this application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to

disclose material information as defined in 37 CFR §1.56(a) which occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

lications	or PCT		•	nating the U.	S-Benefit	
U.S. Applications				Status (Check One)		
Application Serial No.		U.S. Filing Date	Patented	Pending	Abandoned	
			<u> </u>			
			-		•	
tions Des	signatir	ng the U.S.				
Filing	Date	U.S. Serial No. Assigned			·	
	U.S. Ap	U.S. Application	under 35 U.S  U.S. Applications  II No. U.S. Filing Date  tions Designating the U.S.  Filing Date U.S. Serial No.	under 35 U.S.C. §120  U.S. Applications Sta  II No. U.S. Filing Date Patented  tions Designating the U.S.  Filing Date U.S. Serial No.	U.S. Applications  U.S. Filing Date  Patented  Pending  tions Designating the U.S.  Filing Date  U.S. Serial No.	

# CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) (35 U.S.C. §119(e))

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below:

Applicant	Provisional Application Number	Filing Date
Dennis L. Panicali, et al.	60/410,161	September 12, 2002

**POWER OF ATTORNEY**: As a named inventor, I hereby appoint the following attorney(s) with full powers of association, substitution and revocation to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Ronald I, Eisenstein	(Reg. No. 30,628)	David S. Resnick	(Reg. No. 34,235)	Michael L. Goldman	(Reg. No. 30,727)
Nicole L.M. Valtz	(Reg. No. 47,150)	Leena Karttunen	(37 CFR Sec. 10.9(b)) Georgi	a Evans (Reg. No.	44,957)
Lisa A. Dolak	(Reg. No. 35,491)	Joseph Noto	(Reg. No. 32,163))	Gunnar G. Leinberg	(Reg. No. 35,584)
Eduin V. Markal	(Pog No 40 007)		, •	=	

SEND CORRESPONDENCE TO: David S. Resnick	DIRECT TELEPHONE CALLS TO:
NIXON PEABODY LLP	David S. Resnick
100 Summer Street	(617) 345-6057
Boston, Massachusetts 02110	

	FULL NAME OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	PANICALI	DENNIS	_ L.
2	&	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
1	CITIZENSHIP	Acton	MA	U.S.
	POST OFFICE	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
	ADDRESS	114 Nonset Path	Acton	MA 01720

	FULL NAME OF	LAST NAME	FIRST NAME	MIDDLE NAME
	INVENTOR	LEVY	RONALD	
2	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP
2		Stanford	CA	U.S.
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE
		966 Mears Court	Stanford	CA 94305

	FULL NAME OF INVENTOR	SCHLOM	JEFFREY	MIDDLE NAME		
2 0 3	RESIDENCE & CITIZENSHIP	CITY	STATE OR FOREIGN COUNTRY	COUNTRY OF CITIZENSHIP U.S.		
	POST OFFICE ADDRESS	POST OFFICE ADDRESS	CITY	STATE OR COUNTRY AND ZIP CODE		
		10301 Sorrel Ave.	Potomac	MD 20854		

I hereby further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Signature of Inventor 201 – Dennis L. Panicali	Date:
Signature of Inventor 202 – Ronald Levy	Date:
Signature of Inventor 203 – Jeffrey Schlom	Date:
Jeffryklom	11-18-05

DEC 1 2 200 application of:

Dennis L. Panicali et al.

Application No.:

10/660,369

Group No.:

1614

Filed:

09/11/2003

Examiner:

To be assigned 50187

Confirmation No.: For:

Customer No.: 5464

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE

IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR

**EFFECTS IN VIVO** 

#### CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Linda M. Ginsberg

(type for print name of person mailing paper)

MAIL STOP PETITION

Date

Director of the US Patent and Trademark Office

PO Box 1450

**Alexandria, VA 22313-1450** 

# ASSENT OF ASSIGNEE TO CORRECTION AND/OR ADDITION OF INVENTOR(S)

Name of Assignee:

Therion Biologics Corporation

Address of Assignee: 76 Rogers Street

Cambridge, MA 02142

An assignment from Dennis L. Panicali for Application Serial No. 10/660,369 was recorded in the U.S. Patent and Trademark Office on January 26, 2004 at Reel 014923, Frame 0738.

Application No.:

10/660,369

09/11/2003

Group No.:

1614

John T. Li

Filed: Confirmation No.:

For:

5464

Examiner: Customer No.: To be assigned 50187

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS

IN VIVO

Assignee hereby assents to the correction of inventorship filed herewith.

## RIGHT OF ASSIGNEE TO TAKE ACTION

A "STATEMENT UNDER 37 C.F.R. § 373(b)" is attached.

Date

8/22/05

John T. Li

Patent Counsel

Therion Biologics Corporation



## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Dennis L. Panicali et al.

Application No.:

10/660,369

Group No.:

1614

Filed:

09/11/2003

Examiner:

To be assigned

Confirmation No.:

5464

Customer No.:

50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1

AND LFA-3 AND INDUCE IMMUNOSTIMULATORY

PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN

VIVO

#### CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Date

Linda M. Ginsberg

(type or print name of person mailing pa

(signature of person hailing paper)

MAIL STOP PETITION
Director of the US Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

# STATEMENT UNDER 37 C.F.R. § 3.73(b) ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION

The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

## IDENTIFICATION OF ASSIGNEE

Name of assignee:

Therion Biologics Corporation

Type of assignee:

Corporation

In re application of:

Dennis L. Panicali et al.

Application No.:

10/660,369

09/11/2003

Group No.:

1614

Filed: Confirmation No.:

5464

Examiner: Customer No.: To be assigned 50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE
IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS

IN VIVO

#### PERSON AUTHORIZED TO SIGN

Name of person authorized to sign on behalf of assignee: John T. Li Title of person authorized to sign: Patent Counsel

#### **BASIS OF ASSIGNEE'S INTEREST**

Ownership by the assignee is established as follows:

An assignment from the inventor(s) of the matter identified above, which was recorded in the PTO on January 26, 2004 at Reel 014923, Frame 0738.

#### COPIES OF DOCUMENTS IN CHAIN OF TITLE

Copies of the assignment(s) or other document(s) in the chain of title are attached as follows:

Date: 8/22/05

John T. Li

Title: Patent Counsel

Therion Biologics Corporation



Dennis L. Panicali et al.

Application No.:

Confirmation No.:

10/660,369

Group No.:

1614

Filed:

09/11/2003

Examiner:

To be assigned 50187

For:

5464 Customer No.:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR

**EFFECTS IN VIVO** 

#### CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the MAIL STOP PETITION, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Linda M. Ginsberg

Date

**Alexandria, VA 22313-1450** 

type or print pame of person mailings

(signorare of person mailing paper)

MAIL STOP PETITION
Director of the US Patent and Trademark Office
PO Box 1450

# ASSENT OF ASSIGNEE TO CORRECTION AND/OR ADDITION OF INVENTOR(S)

Name of Assignee: The Board of Trustees of the Leland Stanford Junior University

Address of Assignee: 1705 El Camino Real

Palo Alto, CA 94306

An assignment from Ronald Levy for Application Serial No. 10/660,369 was recorded in the U.S. Patent and Trademark Office was recorded in the U.S. Patent and Trademark Office on January 26, 2004 at Reel 014923, Frame 0734.

Application No

Application No.: Filed:

10/660,369 09/11/2003

Group No.; Examiner: 1614

To be assigned

Confirmation No.:

5464

50187

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL

COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE

IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS

Customer No.:

IN VIVO

Assignee hereby assents to the correction of inventorship filed herewith.

## RIGHT OF ASSIGNEE TO TAKE ACTION

A "STATEMENT UNDER 37 C.F.R. § 373(b)" is attached.

Dec 5, 2005

Date

Katharine Ku

Director, Technology Licensing

Name: Title:

On behalf of The Board of Trustees of the Leland Stanford Junior University





#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis L. Panicali et al.

Application No.:

10/660,369

Group No.:

1614

Filed:

09/11/2003

Examiner:

To be assigned

Confirmation No.:

5464

Customer No.:

50187

For:

TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO

EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1

AND LFA-3 AND INDUCE IMMUNOSTIMULATORY

PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN

**VIVO** 

#### CERTIFICATE OF MAILING (37 C.F.R. SECTION 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

December 7, 2005

Date

Linda M. Ginsberg

(type or print name of person mailing paper

(signature of person mailing paper)

MAIL STOP PETITION
Director of the US Patent and Trademark Office
PO Box 1450
Alexandria, VA 22313-1450

# STATEMENT UNDER 37 C.F.R. § 3.73(b) ESTABLISHING RIGHT OF ASSIGNEE TO TAKE ACTION

The assignee(s) of the entire right, title and interest hereby seek(s) to take action in the PTO in this matter.

## **IDENTIFICATION OF ASSIGNEE**

Name of assignee:

The Board of Trustees of the Leland Stanford Junior University


Type of assignee:

Corporation

Application No.: Filed: Confirmation No.: For:	10/660,369 09/11/2003 5464 TRANSDUCED NEOPLASTIC CELL COSTIMULATORY MOLECULES E IMMUNOSTIMULATORY PROPHY IN VIVO	87.1, ICAM-1, AND LFA-3	3 AND INDUCE
	PERSON AUTHOR	IZED TO SIGN	
Name of person au Title of person aut	uthorized to sign on behalf of a horized to sign:		Allerine Ku atharine Ku irector, Technology Licensin
	BASIS OF ASSIGNE	E'S INTEREST	
Ownership by the	assignee is established as follo	ows:	
9	t from the inventor(s) of the r		ove, which was recorded in
	COPIES OF DOCUMENTS ent(s) or other document(s) in	S IN CHAIN OF T	
Date:		Name: Title:	

In re application of:

Dennis L. Panicali et al.



PATENT

1614

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369

Filed: 09/11/2003 Examiner: To be assigned

Confirmation No.: 5464 Customer No.: 50187

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO

EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1

Group No.:

AND LFA-3 AND INDUCE IMMUNOSTIMULATORY

PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS IN

VIVO

MAIL STOP PETITION Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

## **CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)**

I hereby certify that the attached correspondence comprising:

- 1. Certificate of Mailing (2 pp.);
- 2. Transmittal Form (2 pp.);
- 3. Fee Transmittal in duplicate (2 pp.);
- 4. Amendment, Request and Fee to Delete and/or Add to Original Erroneously Named or Not Named Inventor(s) in Nonprovisional Application Declaration (37 C.F.R. § 1.48(a)) in duplicate (4 pp.);
- 5. Statement of Non-Deceptive Intent to Accompany Request for Correction of Inventorship Under 37 C.F.R. §1.48(a) J. Schlom (1 pg.);
- 6. Supplemental Declaration and Power of Attorney executed by all inventors 3 originals (12 pp.);
- 7. Assent of Assignee to Correction and/or Addition of Inventor(s) Therion Biologics Corporation (2 pp.);
- 8. Statement Under 37 C.F.R. § 3.73(b) Establishing Right of Assignee to Take Action Therion Biologics Corporation (2 pp.);
- 9. Assent of Assignee to Correction and/or Addition of Inventor(s) –The Board of Trustees of the Leland Stanford Junior University (2 pp.);
- 10. Statement Under 37 C.F.R. § 3.73(b) Establishing Right of Assignee to Take Action The Board of Trustees of the Leland Stanford Junior University (2 pp.); and
- 11. Return Receipt Postcard.

Docket No. 700953-54440 PATENT

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dennis L. Panicali et al.

Application No.: 10/660,369 Group No.: 1614

Filed: 09/11/2003 Examiner: To be assigned

Confirmation No.: 5464 Customer No.: 50187

For: TRANSDUCED NEOPLASTIC CELL PREPARATIONS ABLE TO EXPRESS T-CELL COSTIMULATORY MOLECULES B7.1, ICAM-1 AND LFA-3 AND INDUCE

IMMUNOSTIMULATORY PROPHYLACTIC AND THERAPEUTIC ANTI-TUMOR EFFECTS

IN VIVO

is being deposited with the United States Postal Service, with sufficient postage, as first class mail in an envelope addressed to:

MAIL STOP PETITION
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on December 7, 2005.

Linda W. Ginsberg

Agnature of person mailing paper

O I P E 42 005 DEC 1 2 2005

PTO/SB/21 (09-04) Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. **Application Number** 10/660.369 **TRANSMITTAL** Filing Date September 11, 2003 First Named Inventor **FORM** Dennis L. Panicali Art Unit 1614 **Examiner Name** To be assigned (to be used for all correspondence after initial filing) Attorney Docket Number 700953-54440 Total Number of Pages in This Submission **ENCLOSURES** (Check all that apply) After Allowance Communication to TC [X]Fee Transmittal Form Drawing(s) Appeal Communication to Board Licensing-related Papers of Appeals and Interferences Fee Attached Appeal Communication to TC Petition (Appeal Notice, Brief, Reply Brief) Amendment/Reply Petition to Convert to a **Proprietary Information** Provisional Application After Final Power of Attorney, Revocation Status Letter Affidavits/declaration(s) Change of Correspondence Address Other Enclosure(s) (please Identify Terminal Disclaimer below): Extension of Time Request See the attached additional enclosures Request for Refund **Express Abandonment Request** CD, Number of CD(s) Information Disclosure Statement Landscape Table on CD Certified Copy of Priority Remarks Document(s) The Commissioner is hereby authorized to charge any fee deficiency or credit any overpayment to the Nixon Peabody LLP Deposit Account No. 50-0850. Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Firm Name Nixon Peabody LLP Signature Printed name Ronald I. Eisenstein Reg. No. Date 30,628 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an efficience addressed to: from missioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: Signature Date 12/07/2005 Linda M. Ginsbørg Typed or printed name

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



# TRANSMITTAL FORM (PTO/SB/21)

**ADDITIONAL ENCLOSURES** 

		_
Application Number	10/660,369	
Filing Date	September 11, 2003	
First Named Inventor	Dennis L. Panicali	
Art Unit	1614	
Examiner Name	To be assigned	
Attorney Docket Number	700953-54440	

## Certificate of Mailing

Amednment, Request and Fee to Delete and/or Add Inventor

Statement of Non-Deceptive Intent to Accompany Request for Correction of Inventorship

Supplemental Declaration and Power of Attorney

Assent of Assignee to Correction and/or Addition of Inventor - Therion Biologics Corportion

Statement under 37 C.F.R. 3.73(b) - Therion Biologics Corporation

Assent of Assignee to Correction and/or Addition of Inventor - The Board of Trustees of the Leland Stanford Junior University

Statement under 37 C.F.R. 3.73(b) - The Board of Trustees of the Leland Stanford Junior University

Return Receipt Postcard

PTO/SB/17 (12-04v2)

Fee (\$)

Fees Paid (\$)

130.00

250.00

Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE aperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

	n 12/08/20		Complete if Known					
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).			. A	pplication Number	mber 10/660,369			
FEE TRANSMITTAL			F	iling Date	September 11, 2003		3	
For FY 2005			Fi	rst Named Inventor	Denn	is L. Panicali		
		0 07 075 407	E	xaminer Name	To be	e assigned		
Applicant claims small enti	ty status.	See 37 CFR 1.27	_ A	rt Unit	1614			
TOTAL AMOUNT OF PAYMEN	NT (\$)	130.00	Α	ttorney Docket No.	7009	700953-54440		
METHOD OF PAYMENT (c	heck all	that apply)						
Check Credit Card	d $\square_N$	Money Order No	one	Other (please i	dentify):			
X Deposit Account Depos		•		Deposit Account I	•		abody LLP	
For the above-identified				•	-			
X Charge fee(s) ind	•		•				ot for the filing fee	
۰ ۱۰ تا		s) or underpayments of	foo(s)	`		· ·	it for the filling fee	
under 37 CFR 1.1 الشكا	16 and 1.1	17		٠ التيتا				
WARNING: Information on this for information and authorization on F		come public. Credit card i	inform	ation should not be in	cluded o	on this form. Provi	de credit card	
FEE CALCULATION								
1. BASIC FILING, SEARCH	. AND E	XAMINATION FEES	;					
	FILING F	EES SEA	ARCH			ION FEES		
Application Type F	ee (\$)	mall Entity Fee (\$) Fee	(\$) S	mall Entity Fee (\$) Fe	<u>sn</u> e (\$)	nall Entity Fee (\$)	Fees Paid (\$)	
Utility 3	300	150 500	)	250 20	00	100		
Design 2	200	100 100	)	50 13	30	65		
Plant 2	200	100 300	)	150 10	50	80		
Reissue 3	300	150 500	)	250 60	00	300	<del></del>	
Provisional 2	200	100 0	)	0	0	0		
2. EXCESS CLAIM FEES Small Entity Fee Description Fee (\$) Fee (\$)								
Each claim over 20 (including Reissues)						50	25	
Each independent claim over 3 (including Reissues)						200	100	
Multiple dependent claims						360	180	
- 20 or HP =  HP = highest number of total clair	me naid for	x =		<del></del>		<u>Fee (\$)</u>	Fee Paid (\$)	
Indep. Claims Ex	tra Claim	s Fee (\$) Fe	ee Pa	id (\$)				
UB = highest number of independ	ont alaima	X =		<del></del>				

SUBMITTED BY			
Signature	Ronald Firen F (Attorney/Agent) 30,628	Telephone	617-345-6054
Name (Print/Type)	Ronald I. Eisenstein	Date De	cember 7, 2005

(round up to a whole number) x

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50

sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets Extra Sheets Number of each additional 50 or fraction thereof

/ 50 =

Non-English Specification, \$130 fee (no small entity discount)

Other (e.g., late filing surcharge): Petition Fee

3. APPLICATION SIZE FEE

4. OTHER FEE(S)

This collection of information is required by 37 CFR 1.136. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 30 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.